MR fingerprinting for quantification of brain amyloid burden: from development to prospective multi-site external validation

Le résumé fourni par la source

Motivation: A non-invasive amyloid beta (Aβ) imaging technique is needed for objective diagnosis and treatment monitoring of Alzheimer’s disease. Goal(s): To develop and validate an MRF-based method quantifying brain Aβ. Approach: A framework with efficient MRF data acquisition, neural network decoding, and atlas-based segmentation was implemented. A prospective analysis was conducted on external dataset to evaluate its generalizability, repeatability, and correlation with Aβ-PET measurements and clinical cognitive function tests. Results: The method showed high repeatability (CV<2%), significant correlation with Aβ-PET measurements and Montreal Cognitive Assessment test (p=0.015 and 0.020, respectively), and discriminated subject-level Aβ positivity with an AUC of 0.84 on external test set. Impact: The proposed framework is compatible with clinical 3T MRI and offers ‘one-stop’ examination in 10 minutes for patients with cognitive decline by providing structural MRI and Aβ-quantification. Its non-invasive nature facilitates longitudinal evaluation and correlates with Aβ-PET and cognitive function.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.